Suppr超能文献

早期乳腺癌同步整合加量超分割全乳放疗的急性皮肤毒性

Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer.

作者信息

Montero Angel, Ciérvide Raquel, Cañadillas Carmen, Álvarez Beatriz, García-Aranda Mariola, Alonso Rosa, López Mercedes, Chen-Zhao Xin, Alonso Leyre, Valero Jeannete, Sánchez Emilio, Hernando Ovidio, García de Acilu Paz, Fernandez-Letón Pedro, Rubio Carmen

机构信息

Department of Radiation Oncology, HM Hospitales, Madrid, Spain.

Facultad de Ciencias de la Salud, Universidad Camilo José Cela, Madrid, Spain.

出版信息

Clin Transl Radiat Oncol. 2023 Jun 15;41:100651. doi: 10.1016/j.ctro.2023.100651. eCollection 2023 Jul.

Abstract

BACKGROUND

Whole-breast irradiation (WBI) after breast conserving surgery (BCS) is indicated to improve loco-regional control and survival. Former studies showed that addition of tumor bed boost in all age groups significantly improved local control although no apparent impact on overall survival but with an increased risk of worse cosmetic outcome. Even though shortened regimens in 3 weeks are considered the standard, recent studies have shown the non-inferiority of a treatment regimen of 5 fractions in one-week in both locoregional control and toxicity profile, although simultaneous integrated boost (SIB) in this setting has been scarcely studied.

MATERIALS AND METHODS

From March-2020 to March-2022, 383 patients with early breast cancer diagnosis and a median age of 56 years-old (range 30-99)were included in a prospective registry of ultra-hypofractionated WBI up to a total dose of 26 Gy in 5.2 Gy/fraction with a SIB of 29 Gy in 5.8 Gy/fraction in 272 patients (71%), 30-31 Gy in 6-6.2 Gy/fraction in 111 patients (29%) with close/focally affected margins. Radiation treatment was delivered by conformal 3-D technique in 366 patients (95%), VMAT in 16patients (4%) and conformal 3-D with deep inspiration breath hold (DIBH) in 4patients (1%). Ninety-three per cent of patients received endocrine therapy and 43% systemic or targeted chemotherapy. Development of acute skin complications was retrospectively reviewed.

RESULTS

With a median follow-up of 18 months (range 7-31), all patients are alive without evidence of local, regional or distant relapse. Acute tolerance was acceptable, with null o mild toxicity: 182 (48%) and 15 (4%) patients developed skin toxicity grade 1 and 2 respectively; 9 (2%) and 2 (0.5%) patients breast edema grade 1and 2 respectively. No other acute toxicities were observed. We also evaluated development of early delayed complications and observed grade 1 breast edema in 6 patients (2%); grade 1 hyperpigmentation in 20 patients (5%); and grade 1 and 2 breast induration underneath boost region in 10(3%) and 2 patients (0.5%) respectively. We found a statistically significant correlation between the median PTV and presence of skin toxicity (p = 0.028) as well as a significant correlation between late hyperpigmentation with the median PTV (p = 0.007) and the ratio PTV/PTV (p = 0.042).

CONCLUSION

Ultra-hypofractionated WBI + SIB in 5 fractions over one-week is feasible and well tolerated, although longer follow-up is necessary to confirm these results.

摘要

背景

保乳手术后进行全乳照射(WBI)有助于改善局部区域控制和生存率。既往研究表明,在所有年龄组中增加瘤床加量可显著改善局部控制,尽管对总生存率无明显影响,但会增加出现较差美容效果的风险。尽管3周的缩短疗程被视为标准方案,但最近的研究表明,1周内5次分割的治疗方案在局部区域控制和毒性方面并不逊色,尽管在此情况下同步整合加量(SIB)很少被研究。

材料与方法

从2020年3月至2022年3月,383例早期乳腺癌患者被纳入一项前瞻性超分割WBI登记研究,这些患者的中位年龄为56岁(范围30 - 99岁),总剂量达26 Gy,每次分割剂量为5.2 Gy,272例患者(71%)采用SIB,每次分割剂量为5.8 Gy,总剂量为29 Gy;111例患者(29%)切缘接近/局部受侵,每次分割剂量为6 - 6.2 Gy,总剂量为30 - 31 Gy。366例患者(95%)采用适形3D技术进行放射治疗,16例患者(4%)采用容积调强弧形放疗(VMAT),4例患者(1%)采用适形3D联合深度吸气屏气(DIBH)技术。93%的患者接受了内分泌治疗,43%的患者接受了全身或靶向化疗。对急性皮肤并发症的发生情况进行了回顾性分析。

结果

中位随访时间为18个月(范围7 - 31个月),所有患者均存活,无局部、区域或远处复发迹象。急性耐受性良好,无或仅有轻度毒性:182例(48%)和15例(4%)患者分别出现1级和2级皮肤毒性;9例(2%)和2例(0.5%)患者分别出现1级和2级乳腺水肿。未观察到其他急性毒性反应。我们还评估了早期延迟并发症的发生情况,观察到6例患者(2%)出现1级乳腺水肿;20例患者(5%)出现1级色素沉着;分别有10例(3%)和2例(0.5%)患者在加量区域下方出现1级和2级乳腺硬结。我们发现中位计划靶体积(PTV)与皮肤毒性的存在之间存在统计学显著相关性(p = 0.028),晚期色素沉着与中位PTV(p = 0.007)以及PTV/PTV比值(p = 0.042)之间也存在显著相关性。

结论

1周内5次分割的超分割WBI + SIB是可行的且耐受性良好,尽管需要更长时间的随访来证实这些结果。

相似文献

1
Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer.
Clin Transl Radiat Oncol. 2023 Jun 15;41:100651. doi: 10.1016/j.ctro.2023.100651. eCollection 2023 Jul.
4
Comparison of two radiation boost schedules in postlumpectomy patients with breast cancer.
J Cancer Res Ther. 2020 Oct-Dec;16(6):1344-1349. doi: 10.4103/jcrt.JCRT_549_19.
8
Hypofractionated Breast Radiation: Shorter Scheme, Lower Toxicity.
Clin Breast Cancer. 2016 Aug;16(4):262-8. doi: 10.1016/j.clbc.2015.09.012. Epub 2015 Sep 25.

引用本文的文献

1
Volumetric Modulated Arc Therapy for 26 Gy in 5 Fractions Whole Breast Irradiation for Breast Cancer.
Adv Radiat Oncol. 2025 Feb 1;10(4):101733. doi: 10.1016/j.adro.2025.101733. eCollection 2025 Apr.
2
Ultrahypofractionated Adjuvant Breast Radiation Therapy (± Boost) and Virtual Consultations: Patient Perspectives at 1 Year.
Adv Radiat Oncol. 2024 Nov 5;10(1):101668. doi: 10.1016/j.adro.2024.101668. eCollection 2025 Jan.
4
Hypofractionated versus Conventional Postmastectomy Irradiation for Breast Cancer: Comparison of Acute Skin Toxicity.
Breast Cancer (Dove Med Press). 2024 Jul 30;16:423-432. doi: 10.2147/BCTT.S471901. eCollection 2024.
7
Ultra-hypofractionated one-week locoregional radiotherapy for patients with early breast cancer: Acute toxicity results.
Clin Transl Radiat Oncol. 2024 Mar 13;46:100764. doi: 10.1016/j.ctro.2024.100764. eCollection 2024 May.

本文引用的文献

1
Breast-Conserving Surgery or Mastectomy?: Impact on Survival.
Ann Surg Open. 2022 Oct 5;3(4):e205. doi: 10.1097/AS9.0000000000000205. eCollection 2022 Dec.
7
Advances in Breast Cancer Radiotherapy: Implications for Current and Future Practice.
JCO Oncol Pract. 2021 Dec;17(12):697-706. doi: 10.1200/OP.21.00635. Epub 2021 Oct 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验